Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Basic) fell 16000.0% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 6078.43%. This contributed to the annual value of $0.08 for FY2024, which is 11447.5% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' EPS (Basic) stood at -$0.52, which was down 16000.0% from -$0.46 recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' EPS (Basic) ranged from a high of $0.49 in Q4 2024 and a low of -$0.52 during Q3 2025
  • Moreover, its 4-year median value for EPS (Basic) was -$0.2 (2024), whereas its average is -$0.2.
  • Per our database at Business Quant, ARS Pharmaceuticals' EPS (Basic) soared by 79554.99% in 2024 and then crashed by 25384.62% in 2025.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EPS (Basic) stood at -$0.39 in 2022, then soared by 81.89% to -$0.07 in 2023, then soared by 795.55% to $0.49 in 2024, then plummeted by 206.8% to -$0.52 in 2025.
  • Its last three reported values are -$0.52 in Q3 2025, -$0.46 for Q2 2025, and -$0.35 during Q1 2025.